OverviewSuggest Edit

Anixa Biosciences (formerly known as ITUS Corporation) is a biotechnology company providing diagnostic and therapeutic solutions for the early detection of tumor-based cancers. It develops a diagnostic platform called Cchek, a series of non-invasive blood tests which can be used for conventional screening, confirmatory testing, and treatment and recurrence monitoring. The Company also develops chimeric antigen receptor T-cell (CAR-T) based immunotherapy drugs which genetically engineer a patient’s own immune cells to fight cancer. 
TypePublic
Founded1982
HQLos Angeles, US
Websiteanixa.com

Latest Updates

Employees (est.) (Oct 2018)7
Revenue (FY, 2018)$1.1 M(+207%)
Share Price (May 2019)$4.2

Key People/Management at Anixa Biosciences

Amit Kumar

Amit Kumar

Chairman, President & Chief Executive Officer
Michael Catelani

Michael Catelani

Chief Operating Officer and Chief Financial Officer
John Roop

John Roop

Senior Vice President of Engineering
Anthony Campisi

Anthony Campisi

Vice President of Engineering
Show more

Anixa Biosciences Office Locations

Anixa Biosciences has an office in Los Angeles
Los Angeles, US (HQ)
12100 Wilshire Boulevard, 8th Floor
Show all (1)

Anixa Biosciences Financials and Metrics

Anixa Biosciences Revenue

Anixa Biosciences's revenue was reported to be $1.11 m in FY, 2018
USD

Revenue (FY, 2018)

1.1m

Net income (FY, 2018)

(14.2m)

EBIT (FY, 2018)

(14.3m)

Market capitalization (22-May-2019)

82.4m

Closing stock price (22-May-2019)

4.2

Cash (31-Oct-2018)

3.1m
Anixa Biosciences's current market capitalization is $82.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

388.9k3.7m9.3m300.0k362.5k1.1m

Revenue growth, %

152%

General and administrative expense

6.9m

R&D expense

1.6m1.6m6.8m
Quarterly
USDQ2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2016Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.2m95.0k750.0k362.5k

General and administrative expense

990.0k1.9m2.7m

R&D expense

431.1k777.9k1.4m2.9m

Operating expense total

1.6m1.5m1.1m1.2m1.9m4.0m6.0m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

898.2k3.4m4.4m2.5m3.3m3.1m

Accounts Receivable

175.0k400.0k400.0k

Inventories

60.6k126.5k

Current Assets

1.2m6.3m6.9m3.4m7.0m5.5m
Quarterly
USDQ2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2016Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

617.7k3.7m5.2m4.0m2.6m2.9m2.8m4.2m2.6m

Accounts Receivable

828.4k133.3k

Current Assets

3.6m6.4m7.8m6.2m4.8m5.2m5.8m5.7m5.7m

Total Assets

10.5m13.4m10.3m8.6m7.2m7.2m7.5m7.4m7.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(10.1m)(9.6m)(1.4m)(5.0m)(5.0m)(14.2m)

Depreciation and Amortization

18.4k

Inventories

(66.0k)

Accounts Payable

641.3k(868.7k)88.0k107.1k101.7k
Quarterly
USDQ2, 2014Q3, 2014Q3, 2015Q1, 2016Q2, 2016Q2, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(6.9m)(6.5m)(86.6k)(1.6m)(2.9m)(1.4m)(1.9m)(3.3m)(8.9m)

Depreciation and Amortization

3.8k21.3k4.4k7.4k12.4k

Accounts Payable

(14.7k)28.1k(813.3k)655.5k132.0k161.3k(63.4k)(28.2k)(60.9k)

Cash From Operating Activities

(1.7m)(2.0m)2.2m(532.4k)(1.9m)(1.8m)(1.3m)(2.1m)(3.3m)
USDY, 2018

Revenue/Employee

158.9k

Financial Leverage

1.2 x
Show all financial metrics

Anixa Biosciences Online and Social Media Presence

Embed Graph

Anixa Biosciences News and Updates

Anixa Biosciences CEO to Present at the New York Academy of Sciences Symposium on Cancer Immunotherapy

SAN JOSE, Calif., March 27, 2019 /PRNewswire/ -- Dr. Amit Kumar, CEO of Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, will participate in a panel presentation discussing the latest science in immunotherapy at a...

Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA for their CAR-T Therapy

SAN JOSE, Calif., Sept. 5, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) and its research partner, Moffitt Cancer Center, today announced that a pre-IND meeting with the US FDA has been scheduled on Tuesday, October 16, 2018. The meeting is to discuss numerous aspects of the...

ITUS Corporation to Present at Next Generation Dx Summit

SAN JOSE, Calif., Aug. 17, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that CEO, Dr. Amit Kumar, will be presenting at the Next Generation Dx Summit in Washington, D.C., being held on August 20th-24th. Dr. Kumar's presentation, "Liquid Biopsy based on Flow...

ITUS Corporation Releases Results for Cchek™ Breast Cancer Study

SAN JOSE, Calif., July 30, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has released interim data from a breast cancer study using its Cchek™ non-invasive (utilizing a blood sample), artificial intelligence (AI) guided, liquid biopsy cancer detection...

Anixa Biosciences Blogs

Anixa Biosciences CAR-T Cancer Therapy Patent Receives Notice of Allowance

SAN JOSE, Calif., Jan. 24, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for the first patent covering Anixa …

Anixa Biosciences Announces Completion of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic Test

SAN JOSE, Calif., Dec. 19, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it completed a Pre-Submission (Pre-Sub) meeting with the US FDA on December 17, 2018.  …

Anixa Biosciences Presents Positive Data on its Liquid Biopsy for Early Detection of Breast Cancer at AACR Conference

SAN JOSE, Calif., Dec. 3, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, presented the latest data from its ongoing study focusing on early detection of breast cancer, utilizing Cchek™, its artificial …

Anixa Biosciences To Present Cchek™ Breast Cancer Data at AACR Special Conference on Tumor Immunology and Immunotherapy

SAN JOSE, Calif., Nov. 15, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that it will present data from its ongoing studies in breast cancer utilizing Cchek™, Anixa's artificial intell…

Anixa Biosciences Presents Positive Data from its Artificial Intelligence Powered Liquid Biopsy for Prostate Cancer at SITC Conference

SAN JOSE, Calif., Nov. 12, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that its two presentations at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) are now…

Anixa Biosciences Announces Scheduling of Pre-Sub Meeting with FDA for its Cchek™ Cancer Diagnostic Test

SAN JOSE, Calif., Oct. 24, 2018 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that a Pre-Submission (Pre-Sub) meeting with the US FDA has been scheduled on Monday, December 17, 2018.  The m…
Show more

Anixa Biosciences Frequently Asked Questions

  • When was Anixa Biosciences founded?

    Anixa Biosciences was founded in 1982.

  • Who are Anixa Biosciences key executives?

    Anixa Biosciences's key executives are Amit Kumar, Michael Catelani and John Roop.

  • How many employees does Anixa Biosciences have?

    Anixa Biosciences has 7 employees.

  • What is Anixa Biosciences revenue?

    Latest Anixa Biosciences annual revenue is $1.1 m.

  • What is Anixa Biosciences revenue per employee?

    Latest Anixa Biosciences revenue per employee is $158.9 k.

  • Who are Anixa Biosciences competitors?

    Competitors of Anixa Biosciences include Chronix Biomedical, NantOmics and Chembio.

  • Where is Anixa Biosciences headquarters?

    Anixa Biosciences headquarters is located at 12100 Wilshire Boulevard, 8th Floor, Los Angeles.

  • Where are Anixa Biosciences offices?

    Anixa Biosciences has an office in Los Angeles.

  • How many offices does Anixa Biosciences have?

    Anixa Biosciences has 1 office.